Skip to main content
BMXXY logo

bioMérieux S.A. (BMXXY) Stock Price & Analysis

bioMérieux S.A. (BMXXY) — price $10.20 (+0.05%), as of the Nov 19, 2026 trading session; market cap $12.0B.

Educational signal · not a buy or sell recommendation · How to read this

$10.20 +$0.005 (+0.05%) Market Cap $12.0B

bioMérieux S.A. · BMXXY · Healthcare · Medical - Diagnostics & Research

bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • QGEN · Qiagen N.V. · 83 /100
  • ICLR · ICON Public Limited Company · 73 /100
  • CRL · Charles River Laboratories International, Inc. · 70 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$10.20
Change on the day+0.05%
52-week range$7.12–$14.55
Market capitalisation$12.0B—
Price / earnings (trailing)23.07
Shares traded on the day300
Beta (volatility vs the S&P 500)0.62
Dividends per share (last 12 months)$0.11
Dividend yield (last 12 months)1.11%

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $7.25, high $15, latest $10. 1 reported quarter marked. $15 $7.25 high $15 Mar 5, 2026 · Earnings results · no recorded estimate to compare · close $151 Oct 17, 2025 Nov 19, 2026 · $10 $14Oct 17, 2025$14Oct 31, 2025$14Nov 14, 2025$14Nov 28, 2025$12Dec 12, 2025$12Dec 26, 2025$13Jan 9, 2026$15Jan 23, 2026$15Feb 6, 2026$15Feb 20, 2026$15Mar 6, 2026$12Mar 20, 2026$12Apr 2, 2026$11Apr 17, 2026$7.95May 1, 2026$7.95May 15, 2026$9.03May 29, 2026$8.00Jun 12, 2026$8.05Jun 26, 2026$8.04Jul 10, 2026$7.92Jul 24, 2026$8.82Aug 7, 2026$8.23Aug 21, 2026$8.70Sep 4, 2026$8.67Sep 18, 2026$9.04Oct 2, 2026$10Oct 16, 2026$11Oct 30, 2026$11Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Other perspectives

Council score for bioMérieux (BMXXY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Strong
ROE Neutral
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is bioMérieux (BMXXY), and what does it report?

Short answer · as of

The business analyzes biological specimens for infectious diseases, cardiovascular conditions and cancers, while also serving quality-control facilities in food, pharmaceuticals, cosmetics and veterinary markets.

Research dated 2026-09-13.

Hospital laboratories, medical practitioners and blood banks therefore sit beside industrial customers in its demand base.

Reported revenue captures a broader activity set than clinical diagnostics alone. The distinguishing feature is the combination of patient testing and manufacturing microbiology, which exposes bioMérieux to laboratory testing volumes as well as quality-control activity across regulated production environments.

2 · Latest results

What do the latest results show for bioMérieux (BMXXY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of €1.96B.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$2.36B Mar 5, 2026
Latest report · revenue estimate
$1.11B Mar 5, 2026
Latest report · revenue vs estimate
Above estimate Mar 5, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Mar 5, 2026$2.36B$1.11B$0.2302Not available
Sep 4, 2025$2.41B$1.32B$0.1594Not available
Mar 7, 2025$2.15B$1.24B$0.1891Not available
Oct 30, 2024$2.04B$1.04B$0.1952Not available
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026€1.96B€226M€0.19 (diluted)
Q4 FY2025€2.01B€235M€0.20 (diluted)
Q2 FY2025€2.04B€161M€0.14 (diluted)
Q4 FY2024€2.08B€217M€0.18 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for bioMérieux (BMXXY)?

Short answer · as of

The distress and quality screens read Altman Z 6.09 · Piotroski F 7. Trailing ratios: ROE 11.0% · ROA 8.1% · current ratio 2.30 · earnings yield 4.2% · free-cash-flow yield 5.4%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BMXXY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported BMXXY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About BMXXY (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

What does bioMérieux sell to hospital laboratories and industrial control facilities?

bioMérieux provides diagnostic platforms that analyze biological specimens in clinical settings and microbiological tests used for manufacturing quality control. Its customer base therefore extends from hospitals and blood banks to regulated industrial facilities.

Is bioMérieux mainly an infectious-disease testing company?

Infectious-disease detection is central, but the portfolio also addresses cardiovascular conditions, cancers and microbiological quality control. Industrial applications make the company broader than a clinical infectious-disease specialist.

What is the BMXXY stock price today?

The last price recorded for bioMérieux S.A. (BMXXY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Does BMXXY pay a dividend?

Yes. The dividend yield of bioMérieux S.A. (BMXXY) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 31 figures on this page — 25 from Financial Modeling Prep (FMP), 3 with no recorded source and 3 computed by us, formula shown in the register. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • 1. What is bioMérieux (BMXXY), and what does it report?: Sector / industry (provider taxonomy); Business description
  • FAQ: What does bioMérieux sell to hospital laboratories and industrial control facilities?: Business description
  • FAQ: Is bioMérieux mainly an infectious-disease testing company?: Business description; Sector / industry (provider taxonomy)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.